Spinout companies
RDM Principal Investigators have been the founders, or co-founders, of 18 spinout companies since 2010. This is one of the main ways in which we turn research discoveries into innovations that generate impact, and ultimately clinical benefit for patients.
| Company Name | Description | RDM PI | Year |
| Thelior Bio | Target discovery via spatial transcriptomics | Alison Simmons | 2025 |
| Yellowstone Biosciences | Soluble T-cell receptor (TCR)-based therapies | Paresh Vyas | 2024 |
| Eterna Biologics | RNA-targeting medicines | Tatjana Sauka Spengler | 2024 |
| Ramanomics (now Vivid Dx) | New technologies for antimicrobial resistance | Monique Andersson | 2024 |
| Alveogene | Lentiviral-based gene therapies for respiratory diseases | Deborah Gill and Steve Hyde | 2023 |
| IngenOx | Delivery of precision medicine drugs and vaccines for cancer treatment | David Kerr | 2023 |
| Alethiomics (now Alethio Therapeutics) | New methodologies for single cell genomics | Adam Mead and Bethan Psaila | 2023 |
| T-Cypher Bio | T cell receptor based therapeutics for immune-mediated disease | Graham Ogg | 2021 |
| Dark Blue Therapeutics | Research and experimental development on biotechnology | Thomas Milne | 2020 |
| Singula Bio | Developing novel neoantigen-based cell therapies for patients with solid tumours | Vincenzo Cerundolo | 2020 |
| Nucleome Therapeutics | Platform technology based on NG capture-c technique computational pipelines | Jim Hughes and James Davies | 2019 |
| MiroBio (sold) | Treating a range of autoimmune and inflammatory disorders | Simon Davis | 2019 |
| Caristo Diagnostics | Novel biomarkers to detect inflammation and risk in coronary heart disease | Charis Antoniades, Keith Channon and Stefan Neubauer | 2018 |
| Ultromics | Echo Machine Learning Assay | Paul Leeson | 2017 |
| Orbit Discovery | Identifying peptide drugs for a range of chronic diseases | Graham Ogg | 2015 |
| iOx Therapeutics (sold) | Developing a novel cancer immunotherapy | Vincenzo Cerundolo | 2015 |
| Perspectum Diagnostics | Developing solutions for major unmet needs in diagnostic medicine in multiple internal organs | Stefan Neubauer | 2013 |
| Oxford Cancer Biomarkers | Identifying novel genetic SNPs in patients at risk of life-threatening side effects | David Kerr | 2010 |